Because the anti-tumor potential of neutrophils has been recently appreciated in many cancers (71–74), we predict that reversal of neutropenia using GM-CSF may provide the added advantage of sustaining tumor regression in addition to protecting the patient with cancer from infections. Here, CSF2 is linked to cancer.